Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of PTX-100 Monotherapy in Relapsed or Refractory Cutaneous T-Cell Lymphoma
2025-521852-45-00Phase 2Authorised
- Sponsor
- Prescient Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of PTX-100 in cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Prescient Therapeutics. Primary endpoint: Objective response rate (ORR). Planned start Dec 2025; status: authorised.
02
Drugs
PTX-100
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2025-521852-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521852-45-00.